Biomea Fusion, Inc.

NasdaqGS BMEA

Biomea Fusion, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.00

Biomea Fusion, Inc. Dividend Per Share is USD -0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.

Biomea Fusion, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.00, a 0.00% change year over year.
Biomea Fusion, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.00, a 0.00% change year over year.
Biomea Fusion, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.00.

Key data

Date	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)

NasdaqGS: BMEA

Biomea Fusion, Inc.

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road
Employees	107
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends

Past 5 years